Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 2
2017 3
2018 3
2019 1
2020 1
2021 12
2022 8
2023 4
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Baveno VII - Renewing consensus in portal hypertension.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. de Franchis R, et al. J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30. J Hepatol. 2022. PMID: 35120736 Free PMC article. Review.
Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.
Ellegast JM, Alexe G, Hamze A, Lin S, Uckelmann HJ, Rauch PJ, Pimkin M, Ross LS, Dharia NV, Robichaud AL, Conway AS, Khalid D, Perry JA, Wunderlich M, Benajiba L, Pikman Y, Nabet B, Gray NS, Orkin SH, Stegmaier K. Ellegast JM, et al. Among authors: benajiba l. Cancer Discov. 2022 Jul 6;12(7):1760-1781. doi: 10.1158/2159-8290.CD-21-0956. Cancer Discov. 2022. PMID: 35405016 Free PMC article.
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, Ling F, Sodaro G, Meslin PA, Bassil CF, Fenouille N, Hoj J, Washart R, Ang HX, Cerda-Smith C, Chaintreuil P, Jacquel A, Auberger P, Forget A, Itzykson R, Lu M, Lin J, Pierobon M, Sheng Z, Li X, Chilkoti A, Owzar K, Rizzieri DA, Pardee TS, Benajiba L, Petricoin E, Puissant A, Wood KC. Lin KH, et al. Among authors: benajiba l. Nat Cancer. 2022 Jul;3(7):837-851. doi: 10.1038/s43018-022-00394-x. Epub 2022 Jun 6. Nat Cancer. 2022. PMID: 35668193 Free PMC article.
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, Milojevic J, End P, Nidamarthy PK, Junge G, Peffault de Latour R. Risitano AM, et al. Among authors: benajiba l. Lancet Haematol. 2021 May;8(5):e344-e354. doi: 10.1016/S2352-3026(21)00028-4. Epub 2021 Mar 23. Lancet Haematol. 2021. PMID: 33765419 Clinical Trial.
Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule.
Kelly LM, Rutter JC, Lin KH, Ling F, Duchmann M, Latour E, Arang N, Pasquer H, Ho Nhat D, Charles J, Killarney ST, Ang HX, Namor F, Culeux C, Lombard B, Loew D, Swaney DL, Krogan NJ, Brunel L, Carretero É, Verdié P, Amblard M, Fodil S, Huynh T, Sebert M, Adès L, Raffoux E, Fenouille N, Itzykson R, Lobry C, Benajiba L, Forget A, Martin AR, Wood KC, Puissant A. Kelly LM, et al. Among authors: benajiba l. Nat Cancer. 2024 Jul;5(7):1082-1101. doi: 10.1038/s43018-024-00782-5. Epub 2024 May 30. Nat Cancer. 2024. PMID: 38816660
Breakthrough infections in MPN-COVID vaccinated patients.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: benajiba l. Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. Blood Cancer J. 2022. PMID: 36379921 Free PMC article. No abstract available.
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Pasquer H, Daltro de Oliveira R, Vasseur L, Soret-Dulphy J, Maslah N, Zhao LP, Marcault C, Cazaux M, Gauthier N, Verger E, Parquet N, Vainchenker W, Raffoux E, Ugo V, Luque Paz D, Roy L, Lambert WC, Ianotto JC, Lippert E, Giraudier S, Cassinat B, Kiladjian JJ, Benajiba L. Pasquer H, et al. Among authors: benajiba l. Leukemia. 2024 Feb;38(2):326-339. doi: 10.1038/s41375-023-02114-5. Epub 2023 Dec 27. Leukemia. 2024. PMID: 38148396
INA03: A Potent Transferrin-Competitive Antibody-Drug Conjugate against CD71 for Safer Acute Leukemia Treatment.
Bratti M, Stubbs E, Kolodych S, Souchet H, Kelly L, Merlin J, Marchal M, Castellano R, Josselin E, Pasquer H, Benajiba L, Puissant A, Koniev O, Collette Y, Belanger C, Hermine O, Monteiro RC, Launay P. Bratti M, et al. Among authors: benajiba l. Mol Cancer Ther. 2024 Aug 1;23(8):1159-1175. doi: 10.1158/1535-7163.MCT-23-0548. Mol Cancer Ther. 2024. PMID: 38641421
42 results